Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Valeant Loses Money in 1Q, Cuts Outlook, Shares Plunge

By AP | June 8, 2016

LAVAL, Quebec (AP) — Valeant tumbled to a loss in its first quarter and the embattled drug maker, squeezed by higher costs, cut its profit and revenue expectations for the year.

Shares, which have plunged almost 90 percent in the past year, fell more than 14 percent Tuesday.

The Canadian pharmaceutical disclosed last week that it had been served with default notices from two lenders because the first-quarter earnings report had been postponed.

Swamped by government investigations into its business and accounting practices, Valeant posted long-overdue results from 2015 in April.

That same month, CEO J. Michael Pearson was excoriated in a congressional hearing, where lawmakers accused Valeant of gouging patients to reward Wall Street investors.

Valeant’s stock price surged for years, fueled by a strategy of gobbling up smaller companies and raising prices on niche drugs — bypassing the huge research and development investments typical of the drug industry.

But the company’s approach has drawn scrutiny from federal prosecutors, Congress and its own investors.

Shares that traded above $260 around this time last year, fell $4.21 to close at $24.64.

For the three months ended March 31, Valeant lost $373.7 million, or $1.08 per share. That compares with a profit of $97.7 million, or 28 cents per share, a year earlier.

Earnings, adjusted for one-time gains and costs, were $1.27 per share, but that’s well below the $1.42 that Wall Street had expected, according to a survey by Zacks Investment Research.

Selling, general and administrative expenses climbed to $620.2 million, from $507.9 million, while research and development costs increased to $103.1 million from $55.8 million. Amortization and impairments surged to $694.5 million from $365.2 million.

Revenue rose to $2.37 billion from $2.17 billion, mostly because of acquisitions it completed last year. The results beat the $2.35 billion that Wall Street predicted.

Valeant now anticipates a full-year adjusted profit in a range of $6.60 to $7 per share on revenue between $9.9 billion and $10.1 billion. Its prior guidance was for an adjusted profit in a range of $8.50 to $9.50 per share on revenue between $11 billion and $11.2 billion.

Analysts polled by FactSet had expected full-year earnings of $8.43 per share on revenue of $10.9 billion.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE